NO20085326L - Pyrido[3,2-e]pyraziner, deres anvendelser som inhibitorer av fosfodiesterase 10, og fremgangsmater for fremstilling av dem - Google Patents

Pyrido[3,2-e]pyraziner, deres anvendelser som inhibitorer av fosfodiesterase 10, og fremgangsmater for fremstilling av dem

Info

Publication number
NO20085326L
NO20085326L NO20085326A NO20085326A NO20085326L NO 20085326 L NO20085326 L NO 20085326L NO 20085326 A NO20085326 A NO 20085326A NO 20085326 A NO20085326 A NO 20085326A NO 20085326 L NO20085326 L NO 20085326L
Authority
NO
Norway
Prior art keywords
phosphodiesterase
compounds
pyrazines
pyrido
inhibitors
Prior art date
Application number
NO20085326A
Other languages
English (en)
Norwegian (no)
Inventor
Ute Egerland
Rudolf Schindler
Chris Rundfeldt
Hans Stange
Thomas Pfeifer
Norbert Hofgen
Barbara Langen
Original Assignee
Elbion Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Gmbh filed Critical Elbion Gmbh
Publication of NO20085326L publication Critical patent/NO20085326L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20085326A 2006-05-30 2008-12-19 Pyrido[3,2-e]pyraziner, deres anvendelser som inhibitorer av fosfodiesterase 10, og fremgangsmater for fremstilling av dem NO20085326L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80924206P 2006-05-30 2006-05-30
PCT/EP2007/004748 WO2007137820A1 (en) 2006-05-30 2007-05-29 PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM

Publications (1)

Publication Number Publication Date
NO20085326L true NO20085326L (no) 2008-12-19

Family

ID=38441604

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085326A NO20085326L (no) 2006-05-30 2008-12-19 Pyrido[3,2-e]pyraziner, deres anvendelser som inhibitorer av fosfodiesterase 10, og fremgangsmater for fremstilling av dem

Country Status (21)

Country Link
US (2) US7550465B2 (enExample)
EP (1) EP2021342A1 (enExample)
JP (1) JP2009538853A (enExample)
KR (1) KR20090013834A (enExample)
CN (1) CN101454324A (enExample)
AR (1) AR061206A1 (enExample)
AU (1) AU2007267392A1 (enExample)
BR (1) BRPI0712132A2 (enExample)
CA (1) CA2651849A1 (enExample)
CL (1) CL2007001554A1 (enExample)
CR (1) CR10358A (enExample)
GT (1) GT200800265A (enExample)
IL (1) IL193740A0 (enExample)
MX (1) MX2008014569A (enExample)
NO (1) NO20085326L (enExample)
PE (1) PE20080711A1 (enExample)
RU (1) RU2008152440A (enExample)
SV (1) SV2009003048A (enExample)
TW (1) TW200817400A (enExample)
WO (1) WO2007137820A1 (enExample)
ZA (1) ZA200807517B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
ES2599054T3 (es) 2006-12-13 2017-01-31 Aska Pharmaceutical Co., Ltd. Derivados de quinoxalina
US7875618B2 (en) * 2007-11-30 2011-01-25 Wyeth Substituted imidazo[1,5-a]quinoxalines useful as inhibitors of phosphodiesterase 10 for the treatment of neurological and other disorders
WO2009068246A2 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Methods of treating obesity and metabolic disorders
WO2009070583A1 (en) * 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
US20090306092A1 (en) * 2008-05-07 2009-12-10 H. Lundbeck A/S Method for treating cognitive deficits
WO2010054253A1 (en) * 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
DK3135286T3 (da) * 2010-07-20 2023-11-27 Minerva Neurosciences Inc Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af skizofreni og symptomer derpå
PL2595485T3 (pl) * 2010-07-20 2022-06-20 Minerva Neurosciences, Inc. Sposoby zastosowania pochodnych amidów cyklicznych w leczeniu zaburzeń mediowanych przez receptor sigma
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
SG192839A1 (en) 2011-02-18 2013-09-30 Allergan Inc Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
EP2763989A1 (en) * 2011-09-09 2014-08-13 H. Lundbeck A/S Pyridine compounds and uses thereof
MX2014005705A (es) 2011-11-09 2014-09-04 Abbvie Deutschland Carboxamidas heterociclicas utiles como inhibidores de fosfodiesterasa del tipo 10a.
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
MX361539B (es) 2012-04-25 2018-12-10 Takeda Pharmaceuticals Co Compuesto heterociclico nitrogenado.
WO2014010732A1 (ja) * 2012-07-13 2014-01-16 武田薬品工業株式会社 複素環化合物
US20140045856A1 (en) * 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
UY34980A (es) 2012-08-17 2014-03-31 Abbvie Inc Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
RU2015114331A (ru) 2012-09-17 2016-11-10 Эббви Дойчланд Гмбх Унд Ко. Кг Новые соединения в качестве ингибиторов фосфодиэстеразы типа 10а
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
JP6280912B2 (ja) 2013-03-14 2018-02-14 武田薬品工業株式会社 複素環化合物
JP2016510788A (ja) 2013-03-14 2016-04-11 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー ホスホジエステラーゼ１０ａ型の新規な阻害剤化合物
WO2015002230A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 アミド化合物
WO2015002231A1 (ja) 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
BR112018010216B1 (pt) 2015-11-20 2024-02-15 Forma Therapeutics, Inc Purinonas como inibidores da protease específica da ubiquitina 1 e composição farmacêutica compreendendo os referidos compostos
PE20200732A1 (es) 2017-06-21 2020-07-23 Minerva Neurosciences Inc Formas de dosificacion oral y de liberacion controlada gastrorresistentes
WO2020065583A1 (en) 2018-09-28 2020-04-02 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
CN114524808B (zh) * 2022-02-21 2023-10-24 深圳市儿童医院 一种吡唑衍生物及其作为pde10抑制剂的用途
CN114524806B (zh) * 2022-02-22 2024-09-03 深圳市儿童医院 一种三氮唑衍生物及其作为pde10抑制剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
JP3147902B2 (ja) * 1991-06-14 2001-03-19 ファルマシア・アンド・アップジョン・カンパニー イミダゾ〔１，５−ａ〕キノキサリン
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors

Also Published As

Publication number Publication date
EP2021342A1 (en) 2009-02-11
MX2008014569A (es) 2008-12-03
US7550465B2 (en) 2009-06-23
AR061206A1 (es) 2008-08-13
US20080027064A1 (en) 2008-01-31
ZA200807517B (en) 2009-06-24
CL2007001554A1 (es) 2008-01-18
CA2651849A1 (en) 2007-12-06
CR10358A (es) 2009-01-07
US20090239874A1 (en) 2009-09-24
BRPI0712132A2 (pt) 2012-01-17
RU2008152440A (ru) 2010-07-10
IL193740A0 (en) 2009-05-04
JP2009538853A (ja) 2009-11-12
KR20090013834A (ko) 2009-02-05
PE20080711A1 (es) 2008-06-14
GT200800265A (es) 2010-07-22
CN101454324A (zh) 2009-06-10
WO2007137820A1 (en) 2007-12-06
AU2007267392A1 (en) 2007-12-06
SV2009003048A (es) 2009-02-11
TW200817400A (en) 2008-04-16

Similar Documents

Publication Publication Date Title
NO20085326L (no) Pyrido[3,2-e]pyraziner, deres anvendelser som inhibitorer av fosfodiesterase 10, og fremgangsmater for fremstilling av dem
PH12012500778A1 (en) IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
PH12012501749A1 (en) Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
MX2010006748A (es) Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
MY161325A (en) 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
MY153913A (en) 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MX2007013263A (es) Novedosos derivados oxadiazol y su uso medico.
WO2009097287A9 (en) Compounds and compositions as kinase inhibitors
NO20074207L (no) Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
NZ596053A (en) 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
NO20076659L (no) Pyrrolo(2,3-B)pyridinderivater som protein kinase inhibitorer
NO20091683L (no) Kjemiske forbindelser
MX2007002592A (es) Derivados 4,6 -dialcoxi - cinnolina 4 - sustituidos como inhibidores de la fosfodiesterasa 10 para el tratamiento de sindromes psiquiatricos o neurologicos.
WO2009158467A3 (en) Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors
WO2010006130A3 (en) Pde-10 inhibitors
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
MX362197B (es) Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
NO20064974L (no) terapeutiske midler
MX347632B (es) Derivados de 6,7-dihidro-3h-oxazolo[3,4-a]pirazin-5,8-diona.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application